APX001: A New Antifungal with Activity Against Candida auris
OCT 16, 2017 | CONTAGION® EDITORIAL STAFF
Ciara Kennedy, PhD, president and CEO of Amplyx Pharmaceuticals, Inc, explains that by targeting an enzyme with the fungal cell, APX001 is able to inhibit the formation of the fungal cell wall, thereby decreasing the virulence, pathogenicity, and biofilm-producing capabilities of the fungus. Data from phase 1 studies are promising for this new antifungal to be able to be administered in both intravenous and oral forms, providing physicians with a new opportunity for continuum of care, using the same mechanism of action.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512